Call for papers


Call for papers

We at Ophthalmology Times Europe are dedicated to providing current and informative articles that will benefit our readers and their daily practice. As the ophthalmology industry evolves, we want you to keep us, and our readers informed of what's new and exciting. We therefore invite you to submit papers on scientific advances, breaking news or editorials on the important issues that are shaping your industry.

It is our mission to be the European forum for ophthalmologists to communicate practical experience, clinical knowledge, discoveries and applications, in order to promote improvements to medical practice and, ultimately, the health of your patients.

Please take a look at our Article Submission Guidelines or contact the editorial department to find out how you can have your voice heard by more than 20,500 ophthalmologists around Europe.

  • If you would like to submit an abstract or synopsis for consideration to Ophthalmology Times Europe, please click here. Thank you.

  • If you would like to submit a press release to Ophthalmology Times Europe, please click here. Thank you.

  • If you would like to submit an event for inclusion in Ophthalmology Times Europe's calendar, please click here. Thank you.
Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.